|
KALV | Kalvista Pharmaceuticals, Inc. |
|
|
KALV | Kalvista Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.22 |
| Leverage | 87.21% |
| Market Cap | $ 452.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -209.2m |
| Margin | -1073.87% |
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.